PURPOSE: To evaluate the role of bone marrow-derived mononuclear cells (BMC) in rat bile duct ligation (BDL) model. METHODS: Wistar rats were categorized into four Groups A-D. Normal liver biopsy was taken from Group A. BDL model was created in Groups B and C (15 each). Normal saline and BMC were injected through portal vein (PV) in Groups B and C, respectively. In Group D (healthy rat), only BMC were infused through PV. Groups B and C were compared for body weight, liver functions, survival, and histopathological changes. RESULTS: Serum bilirubin was lower in Group C at day 6 (p = 0.0010). Median survival time was 5 (4, 6) and 13 (9, 17) days in Groups B and C (p = 0.0147), respectively. Portal edema (p = 0.013) and portal inflammation (p = 0.025) were less in Group C vs Group B. On post hoc subgroup analysis of rats surviving 8-26 days, portal inflammation (p = 0.004), bile duct proliferation (p = 0.016) and portal fibrosis (p = 0.038) were less in Group C vs Group B. Hepatocyte regeneration was found in four rats in Group C. CD34-positive cells were prominent in sinusoids and portal tracts in the BDL rat model. CONCLUSIONS: BMC have shown to delay fibrosis, facilitate hepatocyte regeneration and improve survival in an experimental BDL model, with potential clinical implication in obstructive cholangiopathy.
PURPOSE: To evaluate the role of bone marrow-derived mononuclear cells (BMC) in rat bile duct ligation (BDL) model. METHODS:Wistar rats were categorized into four Groups A-D. Normal liver biopsy was taken from Group A. BDL model was created in Groups B and C (15 each). Normal saline and BMC were injected through portal vein (PV) in Groups B and C, respectively. In Group D (healthy rat), only BMC were infused through PV. Groups B and C were compared for body weight, liver functions, survival, and histopathological changes. RESULTS: Serum bilirubin was lower in Group C at day 6 (p = 0.0010). Median survival time was 5 (4, 6) and 13 (9, 17) days in Groups B and C (p = 0.0147), respectively. Portal edema (p = 0.013) and portal inflammation (p = 0.025) were less in Group C vs Group B. On post hoc subgroup analysis of rats surviving 8-26 days, portal inflammation (p = 0.004), bile duct proliferation (p = 0.016) and portal fibrosis (p = 0.038) were less in Group C vs Group B. Hepatocyte regeneration was found in four rats in Group C. CD34-positive cells were prominent in sinusoids and portal tracts in the BDL rat model. CONCLUSIONS:BMC have shown to delay fibrosis, facilitate hepatocyte regeneration and improve survival in an experimental BDL model, with potential clinical implication in obstructive cholangiopathy.
Authors: E Lagasse; H Connors; M Al-Dhalimy; M Reitsma; M Dohse; L Osborne; X Wang; M Finegold; I L Weissman; M Grompe Journal: Nat Med Date: 2000-11 Impact factor: 53.440
Authors: Yoon-Young Jang; Michael I Collector; Stephen B Baylin; Anna Mae Diehl; Saul J Sharkis Journal: Nat Cell Biol Date: 2004-05-09 Impact factor: 28.824
Authors: Ryang Hwa Lee; Andrey A Pulin; Min Jeong Seo; Daniel J Kota; Joni Ylostalo; Benjamin L Larson; Laura Semprun-Prieto; Patrice Delafontaine; Darwin J Prockop Journal: Cell Stem Cell Date: 2009-07-02 Impact factor: 24.633
Authors: Joanna Maria Lotowska; Maria Elzbieta Sobaniec-Lotowska; Dariusz Marek Lebensztejn; Urszula Daniluk; Piotr Sobaniec; Krzysztof Sendrowski; Jaroslaw Daniluk; Joanna Reszec; Wojciech Debek Journal: Gastroenterol Res Pract Date: 2017-07-09 Impact factor: 2.260